Snapshot from Aug 24, 2026 at 07:00 UTC. For live data and tracking: View Live
Entities / People / Ziyad Al-Aly
Person

Ziyad Al-Aly

Tracked across 2 events · 12 articles · First seen Jul 13, 2026 · Last active Aug 01, 2026

Sentiment
10
Attention
4
Events
2
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
Events (2)
4 0
Tech
GLP-1 drugs cancer risk debate
In the weeks around the 2026 annual meeting of the American Society of Clinical Oncology, a wave of studies and media coverage suggested that GLP-1 drugs such as Ozempic might lower cancer risk. Observational studies…
Impact: As the author of the expert commentary, Al-Aly provides a critical perspective, urging caution against overinterpreting observational data. His views may influence public and investor perception.
Jul 13, 2026 · 6 articles
4 20
Domestic
VA launches semaglutide alcohol use disorder trial
Impact: Al-Aly led the March analysis that found lower rates of substance use disorders in GLP-1 users, providing key evidence for the trial.
Jul 30, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Ziyad Al-Aly live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.